OcuMedic

Controlled Drug Delivery via a Contact Lens to replace eye drops for quicker recovery and health care savings

OcuMedic's platform technology is comprised of a therapeutic contact lens/ FREEDOM™ Bandages Lens made of Silicone hydrogel (SiHy) matrix and formulated with a drug of choice, non-covalently bound to the matrix of lens during synthesis for controlled release.

All lens design parameters meet or exceed FDA APPROVAL REQUIREMENTS FOR AN EXTENDED WEAR LENS! Both the drug and lens material have EXTENSIVE SAFETY HISTORIES AND ARE EXTENSIVELY USED WORLDWIDE. Both the Lens material and drug ARE OFF PATENT.

The unique engineering of the therapeutic lenses allows for the following advantages:

• Controlled release of the drug: can "dial-in" the speed and potency of delivery
• Continuous release of the drug: can be worn continuously, as the SIHY material is FDA approved for day, and night wear up to 7 days.
• Non-invasive, Safe and Effective: In vivo studies showed FREEDOM™ BandagesLenses are well tolerated, show no adverse events and deliver more drug than drops with (26x higher bioavailability)
• As Prescribed treatment gives the provider the confidence that prescribed drug has been delivered - Reducing the likelihood of recalls
• Delivered at the Point of Care by the provider and removed during weekly check-ups improves patient compliance and speeds recovery time
• Providers' Business Advantage: Presents opportunity for inventory and onsite disbursement of the product for both Ophthalmologists and Optometrists benefiting co-management
• Shorter time to commercialization – Silicone Hydrogel and off-patent drugs used for initial products have precedent for safe & effective use as – 505 (b)(2) regulatory path

The platform technology has been tested for use with combination, or monotherapy for treatment of pain and inflammation, Dry Eye Syndrome, Glaucoma, comfort agents and 10 other drugs for other ophthalmological indications.

Executive Team

· Keith D. Ignotz, MBA President & CEO Prior Executive roles: Freedom Meditech; DiaKine Therapeutics; SpectRx; Allergan Humphrey Division of Allergan · Mark Byrne, Ph.D. Founder & CTO Distinguished Professor Dean of Chemical and Biomedical Engineering Rowan University · Michael Schopler, MBA, COO Chemical engineer / extensive business development experience